vs
Side-by-side financial comparison of NLIGHT, INC. (LASR) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $81.2M, roughly 1.3× NLIGHT, INC.). NLIGHT, INC. runs the higher net margin — -6.0% vs -29.4%, a 23.4% gap on every dollar of revenue. On growth, NLIGHT, INC. posted the faster year-over-year revenue change (71.3% vs 16.9%). NLIGHT, INC. produced more free cash flow last quarter ($15.9M vs $-34.8M).
nLight Inc. is a global developer and manufacturer of high-performance semiconductor lasers, fiber lasers, and related optical components. Its products serve key segments including industrial precision manufacturing, aerospace and defense, medical equipment, and advanced research, with customers across North America, Europe, and Asia Pacific.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
LASR vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $81.2M | $103.7M |
| Net Profit | $-4.9M | $-30.5M |
| Gross Margin | 30.7% | 52.0% |
| Operating Margin | -6.7% | -31.7% |
| Net Margin | -6.0% | -29.4% |
| Revenue YoY | 71.3% | 16.9% |
| Net Profit YoY | 80.3% | 3.4% |
| EPS (diluted) | $-0.10 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $81.2M | $103.7M | ||
| Q3 25 | $66.7M | — | ||
| Q2 25 | $61.7M | — | ||
| Q1 25 | $51.7M | — | ||
| Q4 24 | $47.4M | — | ||
| Q3 24 | $56.1M | — | ||
| Q2 24 | $50.5M | — | ||
| Q1 24 | $44.5M | — |
| Q4 25 | $-4.9M | $-30.5M | ||
| Q3 25 | $-6.9M | — | ||
| Q2 25 | $-3.6M | — | ||
| Q1 25 | $-8.1M | — | ||
| Q4 24 | $-25.0M | — | ||
| Q3 24 | $-10.3M | — | ||
| Q2 24 | $-11.7M | — | ||
| Q1 24 | $-13.8M | — |
| Q4 25 | 30.7% | 52.0% | ||
| Q3 25 | 31.1% | — | ||
| Q2 25 | 29.9% | — | ||
| Q1 25 | 26.7% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | 23.5% | — | ||
| Q1 24 | 16.8% | — |
| Q4 25 | -6.7% | -31.7% | ||
| Q3 25 | -10.9% | — | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | -18.6% | — | ||
| Q4 24 | -55.8% | — | ||
| Q3 24 | -21.0% | — | ||
| Q2 24 | -25.1% | — | ||
| Q1 24 | -33.1% | — |
| Q4 25 | -6.0% | -29.4% | ||
| Q3 25 | -10.3% | — | ||
| Q2 25 | -5.8% | — | ||
| Q1 25 | -15.7% | — | ||
| Q4 24 | -52.7% | — | ||
| Q3 24 | -18.4% | — | ||
| Q2 24 | -23.2% | — | ||
| Q1 24 | -30.9% | — |
| Q4 25 | $-0.10 | $-0.50 | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $-0.07 | — | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-0.52 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.25 | — | ||
| Q1 24 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.7M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $226.7M | $456.1M |
| Total Assets | $315.2M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.7M | $197.9M | ||
| Q3 25 | $81.1M | — | ||
| Q2 25 | $78.8M | — | ||
| Q1 25 | $82.2M | — | ||
| Q4 24 | $65.8M | — | ||
| Q3 24 | $41.5M | — | ||
| Q2 24 | $49.4M | — | ||
| Q1 24 | $61.3M | — |
| Q4 25 | $226.7M | $456.1M | ||
| Q3 25 | $218.5M | — | ||
| Q2 25 | $216.0M | — | ||
| Q1 25 | $212.8M | — | ||
| Q4 24 | $216.4M | — | ||
| Q3 24 | $235.3M | — | ||
| Q2 24 | $239.5M | — | ||
| Q1 24 | $244.4M | — |
| Q4 25 | $315.2M | $638.1M | ||
| Q3 25 | $298.7M | — | ||
| Q2 25 | $295.3M | — | ||
| Q1 25 | $290.0M | — | ||
| Q4 24 | $270.2M | — | ||
| Q3 24 | $291.3M | — | ||
| Q2 24 | $294.3M | — | ||
| Q1 24 | $302.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.5M | $-24.8M |
| Free Cash FlowOCF − Capex | $15.9M | $-34.8M |
| FCF MarginFCF / Revenue | 19.6% | -33.5% |
| Capex IntensityCapex / Revenue | 2.0% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.5M | $-24.8M | ||
| Q3 25 | $5.2M | — | ||
| Q2 25 | $-1.4M | — | ||
| Q1 25 | $-20.0K | — | ||
| Q4 24 | $-3.9M | — | ||
| Q3 24 | $-5.6M | — | ||
| Q2 24 | $-4.2M | — | ||
| Q1 24 | $11.4M | — |
| Q4 25 | $15.9M | $-34.8M | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $-3.8M | — | ||
| Q1 25 | $-2.3M | — | ||
| Q4 24 | $-6.5M | — | ||
| Q3 24 | $-7.2M | — | ||
| Q2 24 | $-6.4M | — | ||
| Q1 24 | $9.8M | — |
| Q4 25 | 19.6% | -33.5% | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | -6.1% | — | ||
| Q1 25 | -4.5% | — | ||
| Q4 24 | -13.7% | — | ||
| Q3 24 | -12.9% | — | ||
| Q2 24 | -12.6% | — | ||
| Q1 24 | 22.1% | — |
| Q4 25 | 2.0% | 9.6% | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 4.2% | — | ||
| Q1 24 | 3.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LASR
| Aerospaceand Defense | $56.3M | 69% |
| Microfabrication | $14.2M | 18% |
| Industrial | $10.7M | 13% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
